# Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)

> **NCT00739830** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 130 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** ridaforolimus
- **DRUG:** medroxyprogesterone acetate tablets OR megestrol acetate
- **DRUG:** chemotherapy

## Key facts

- **NCT ID:** NCT00739830
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2011-02
- **Final completion:** 2012-07
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739830, "Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00739830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*